Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
158.60
-7.28 (-4.39%)
At close: Oct 16, 2026, 4:00 PM EDT
159.44
+0.84 (0.53%)
Pre-market: Oct 19, 2026, 4:52 AM EDT
Guardant Health Employees
As of December 31, 2025, Guardant Health had 2,506 total employees, including 2,490 full-time and 16 part-time employees. The number of employees increased by 485 or 24.00% compared to the previous year. That makes Guardant Health the 8,951st largest employer in the world and 1,560th in the United States.
Employees
2,506
Change (1Y)
485
Growth (1Y)
24.00%
Revenue / Employee
$472,109
Profits / Employee
-$180,940
Market Cap
21.28B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 2,506 | 485 | 24.00% | 2,490 | 16 |
| Dec 31, 2024 | 2,021 | 242 | 13.60% | 1,999 | 22 |
| Dec 31, 2023 | 1,779 | -14 | -0.78% | 1,768 | 11 |
| Dec 31, 2022 | 1,793 | 420 | 30.59% | 1,793 | 0 |
| Dec 31, 2021 | 1,373 | 509 | 58.91% | 1,373 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IQVIA Holdings | 93,000 |
| Labcorp Holdings | 71,000 |
| Quest Diagnostics | 57,000 |
| ICON Public Limited Company | 40,100 |
| Charles River Laboratories International | 19,700 |
| Mettler-Toledo International | 18,100 |
| Revvity | 11,000 |
| IDEXX Laboratories | 11,000 |
GH News
- 3 days ago - TwinStrand Biosciences says US PTABL rejects Guardant challenge to patent - TheFly
- 3 days ago - Guardant presents data from role of blood-based testing in CRC screening - TheFly
- 3 days ago - Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests - Business Wire
- 6 days ago - Guardant Health price target raised to $200 from $185 at Morgan Stanley - TheFly
- 9 days ago - Guardant Health price target raised to $200 from $195 at BofA - TheFly
- 10 days ago - Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion - TheFly
- 10 days ago - Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer - Business Wire
- 10 days ago - Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026 - Business Wire